Objective—To evaluate whether pedal bacteremia develops following regional IV perfusion (RIVP) of a 2% lidocaine hydrochloride solution in cattle with deep digital sepsis (DDS) and to determine which bacterial pathogens are most commonly isolated from the pedal circulation.
Design—Prospective observational cohort study.
Animals—9 adult cattle with DDS in 10 limbs and 10 healthy adult cattle with no evidence of lameness or digital infection.
Procedures—Blood samples were obtained aseptically from the dorsal common digital vein immediately following tourniquet application and 30 to 60 minutes after aseptic RIVP with a 2% lidocaine solution. Aerobic and anaerobic bacterial cultures were performed on all samples collected. For cattle with DDS, clinical examination with or without debridement of digital lesions was performed after RIVP.
Results—Bacteria were isolated from pedal blood prior to RIVP in 1 cow with DDS and after RIVP and examination with or without debridement in that cow and 4 additional cattle with DDS. Bacteria were not isolated from any blood sample obtained from the healthy cattle. Of the 8 bacterial isolates identified, 5 were gram-positive facultative anaerobes. Cattle with DDS were significantly more likely to develop bacteremia in the pedal circulation than were healthy cattle following RIVP.
Conclusions and Clinical Relevance—Results indicated that bacteremia may be present in the pedal circulation before and following RIVP and examination with or without debridement in cattle with DDS. Thus, systemic or local antimicrobial treatment might be warranted prior to or concurrently with RIVP in cattle with DDS.
Objective—To compare effects of administration of a modified-live respiratory virus vaccine once with administration of the same vaccine twice on the health and performance of cattle.
Design—Randomized, controlled trial.
Animals—612 mixed-breed male cattle with unknown health histories.
Procedures—Cattle were randomly assigned to 1 of 2 treatment groups (single vaccination treatment group [SVAC group] vs revaccination treatment group [REVAC group]) during the preconditioning phase of production. All cattle were given a modified-live respiratory virus vaccine. Eleven days later, REVAC group cattle received a second injection of the same vaccine. During the finishing phase of production, cattle from each treatment group were either vaccinated a third time with the modified-live respiratory virus vaccine or given no vaccine. Health observations were performed daily. Blood and performance variables were measured throughout the experiment.
Results—During preconditioning, no significant differences were observed in performance or antibody production between groups. Morbidity rate from bovine respiratory disease was lower for SVAC group cattle; however, days to first treatment for bovine respiratory disease were not different between groups. No significant differences in body weights, daily gains, or dry-matter intake between groups were observed during the finishing phase. Revaccination treatment group cattle had improved feed efficiency regardless of vaccination protocol in the finishing phase.
Conclusions and Clinical Relevance—Vaccination once with a modified-live respiratory virus vaccine was as efficacious as vaccination twice in the prevention of bovine respiratory disease of high-risk cattle, although feed efficiency was improved in REVAC group cattle during the finishing period.
Objective—To identify any adverse effects on health or performance in young dairy calves fed clinoptilolite mixed with milk replacer.
Animals—26 male Holstein calves (1 to 7 days old).
Procedures—Twice daily for 28 days, calves were fed milk replacer with no clinoptilolite (control group; n = 8), 0.5% clinoptilolite (low-dosage group; 9), or 2% clinoptilolite (high-dosage group; 9); each calf consumed approximately 12% of its body weight (based on the replacer solids in the milk replacer mixture)/d. For each calf, subjective health assessments, weight and rectal temperature measurements, and CBC and serum biochemical analyses were performed at intervals. All calves underwent necropsy.
Results—2 calves were euthanized during the experiment because of bronchopneumonia or enteritis. Body weight and average daily gain did not differ among treatment groups. The percentage of monocytes and serum total protein concentration in the low-dosage group were higher than values in the control and high-dosage groups. Compared with values for either clinoptilolite-treated group, BUN concentration was greater in the control group. Serum globulin concentration differed significantly among groups (2.77, 2.50, and 2.36 g/dL in the low-dosage, control, and high-dosage groups, respectively). At necropsy, gross lesions associated with clinoptilolite treatment were not detected in any of the calves.
Conclusions and Clinical Relevance—Even under stressful conditions, clinoptilolite fed at low or high dosages did not affect the performance of dairy calves and had no negative effect on WBC count and blood metabolite concentrations and enzyme activities. Clinoptilolite ingestion was not associated with treatment-specific gross changes.
Objective—To evaluate exhaled N2O (eN2O), exhaled CO (eCO), and serum haptoglobin concentrations as diagnostic criteria for bovine respiratory disease (BRD) and determine whether a combination of biomarkers would be useful for predicting health outcomes of heifer calves.
Animals—337 heifer calves newly arrived at a feedlot.
Procedures—Body weights, serum haptoglobin concentrations, and rumen temperatures were determined. Calves (n = 183) were randomly selected for breath sampling. Variables were compared among calves that remained healthy and those requiring treatment.
Results—Body weight at the time of first and second antimicrobial treatments did not differ from that at arrival, whereas body weight at the time of third antimicrobial treatment was lower. Temperature was lower at arrival, compared with that during antimicrobial treatment. Ratio of eN2O:eCO2 was lowest at arrival, intermediate at the first and second antimicrobial treatments, and greatest at the third antimicrobial treatment. Ratio of eCO:eCO2 was greater at times of antimicrobial treatment, compared with arrival. Concentration of serum haptoglobin was greatest at the time of the first antimicrobial treatment, lowest at the times of second and third treatments, and intermediate at arrival. Arrival ratios of eN2O: eCO2 and eCO:eCO2 and concentration of haptoglobin did not differ among heifers subsequently treated 1, 2, or 3 times.
Conclusions and Clinical Relevance—Although breath analysis was successfully implemented in a research feedlot, arrival rumen temperature, eN2O, eCO, and haptoglobin concentration were not accurate in predicting occurrence of BRD during a preconditioning program. However, these biomarkers might support the diagnosis of BRD.
Objective—To evaluate serum haptoglobin concentration at feedlot arrival and subsequent performance and morbidity and mortality rates of calves that developed bovine respiratory disease.
Animals—360 heifer calves and 416 steer and bull calves.
Procedures—Serum samples were obtained from cattle at the time of arrival to a feedlot (day −1) and analyzed for haptoglobin concentration. In experiment 1, calves were classified into groups with a low (< 1.0 μg/mL), medium (1.0 to 3.0 μg/mL), or high (> 3.0 μg/mL) serum haptoglobin concentration and allotted into pens on the basis of group. In experiment 2, calves were classified as having or not having detectable serum haptoglobin concentrations.
Results—In experiment 1, average daily gain from days 1 to 7 decreased as haptoglobin concentration increased. Dry-matter intake (DMI) from days 1 to 21 decreased with increasing haptoglobin concentration, and DMI typically decreased from days 1 to 63. Total bovine respiratory disease morbidity rate typically increased with increasing haptoglobin concentration. At harvest, no differences in carcass characteristics were observed on the basis of haptoglobin concentration. In experiment 2, cattle with measureable serum haptoglobin concentrations at arrival weighed less throughout the experiment, gained less from days 1 to 7, and had lower DMI from days 1 to 42. Overall morbidity rate was not different between groups, but cattle with detectable serum haptoglobin concentrations had higher odds of being treated 3 times.
Conclusions and Clinical Relevance—Serum haptoglobin concentration in cattle at the time of feedlot arrival was not associated with overall performance but may have limited merit for making decisions regarding targeted prophylactic treatment.
Objective—To determine efficacy of a modified-live virus (MLV) vaccine containing bovine viral diarrhea virus (BVDV) 1a and 2a against fetal infection in heifers exposed to cattle persistently infected (PI) with BVDV subtype 1 b.
Animals—50 heifers and their fetuses.
Procedures—Susceptible heifers received a placebo vaccine administered IM or a vaccine containing MLV strains of BVDV1a and BVDV2a administered IM or SC. On day 124 (64 to 89 days of gestation), 50 pregnant heifers (20 vaccinated SC, 20 vaccinated IM, and 10 control heifers) were challenge exposed to 8 PI cattle. On days 207 to 209, fetuses were recovered from heifers and used for testing.
Results—2 control heifers aborted following challenge exposure; both fetuses were unavailable for testing. Eleven fetuses (8 control heifers and 1 IM and 2 SC vaccinates) were positive for BVDV via virus isolation (VI) and for BVDV antigen via immunohistochemical analysis in multiple tissues. Two additional fetuses from IM vaccinates were considered exposed to BVDV (one was seropositive for BVDV and the second was positive via VI in fetal tissues). A third fetus in the SC vaccinates was positive for BVDV via VI from serum alone. Vaccination against BVDV provided fetal protection in IM vaccinated (17/20) and SC vaccinated (17/20) heifers, but all control heifers (10/10) were considered infected.
Conclusions and Clinical Relevance—1 dose of a BVDV1a and 2a MLV vaccine administered SC or IM prior to breeding helped protect against fetal infection in pregnant heifers exposed to cattle PI with BVDV1b.
Objective—To compare antibody responses, feedlot morbidity and mortality rates, feedlot performance, and carcass value for calves vaccinated with 1 of 2 vaccination strategies and for unvaccinated control calves.
Design—Randomized controlled clinical trial.
Animals—451 beef steers and heifers.
Procedures—Calves were vaccinated with a modified-live infectious bovine rhinotracheitis virus (IBRV), bovine viral diarrhea virus types 1 (BVDV1) and 2 (BVDV2), parainfluenza type 3 virus, and bovine respiratory syncytial virus vaccine and Mannheimia haemolytica and Pasteurella multocida bacterin-toxoid at approximately 67 and 190 days of age (group 1; n = 151) or at approximately 167 and 190 days of age (group 2; 150) or were not vaccinated (control; 150). Serum antibody titers were measured at approximately 2, 67, 167, 190, and 232 days of age. Morbidity and mortality rates, feedlot performance, and carcass value were recorded for 361 calves shipped to feedlots.
Results—Percentages of calves seroconverting to IBRV, BVDV1, and BVDV2 were significantly higher for groups 1 and 2 than for the control group. Mean treatment costs were significantly lower for vaccinated than for control calves, and mean mortality rate was significantly higher for control calves than for group 1 calves. Feedlot performance and carcass value did not vary significantly among groups.
Conclusions and Clinical Relevance—Results suggested that vaccination of beef calves with a 5-antigen modified-live virus vaccine at 67 and 190 days of age was as effective in terms of immunologic responses as was vaccination at 167 and 190 days of age.